http://orcid.org/0000-0001-6998-662X
References
- Patnaik MM, Tefferi A. Chronic myelomonocytic leukemia: 2016 update on diagnosis, risk stratification, and management. Am J Hematol. 2016;91:631–642.
- Bowen JM, Perry AM, Quist E, et al. Extramedullary hematopoiesis in a sentinel lymph node as an early sign of chronic myelomonocytic leukemia. Case Rep Pathol. 2015;2015:594970.
- Bradford CR, Smith SR, Wallis JP. Pericardial extramedullary haemopoiesis in chronic myelomonocytic leukaemia. J Clin Pathol. 1993;46:674–675.
- Mathew RA, Bennett JM, Liu JJ, et al. Cutaneous manifestations in CMML: indication of disease acceleration or transformation to AML and review of the literature. Leuk Res. 2012;36:72–80.
- Kaddu S, Zenahlik P, Beham-Schmid C, et al. Specific cutaneous infiltrates in patients with myelogenous leukemia: a clinicopathologic study of 26 patients with assessment of diagnostic criteria. J Am Acad Dermatol. 1999;40:966–978.
- Paydas S, Zorludemir S, Ergin M. Granulocytic sarcoma: 32 cases and review of the literature. Leuk Lymphoma. 2006;47:2527–2541.
- Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–2405.
- Patnaik MM, Barraco D, Lasho TL, et al. DNMT3A mutations are associated with inferior overall and leukemia-free survival in chronic myelomonocytic leukemia. Am J Hematol. 2017;92:56–61.
- Patnaik MM, Lasho TL, Vijayvargiya P, et al. Prognostic interaction between ASXL1 and TET2 mutations in chronic myelomonocytic leukemia. Blood Cancer J. 2016;6:e385.